Search
for
Sort by
Research 30 of 1000+
- Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
- In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions
- Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
- - Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
- Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake
- Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
- Analysis of Dermal Papilla Cell Interactome Using STRING Database to Profile the ex Vivo Hair Growth Inhibition Effect of a Vinca Alkaloid Drug, Colchicine
- Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- Cerebral Ischemia Related to Isotretinoin; Venlafaxine-Induced Alopecia; Cognitive Dysfunction with Tolterodine; Retinal Artery Occlusion after Injection of Long-Acting Risperidone; Olanzapine-Induced Chylomicronemia Presenting as Pancreatitis; Metabolic Effects of the Atypical Antipsychotics – an Editorial; Another Drug-Induced Pancreatitis – This One Caused by a Tyrosine Kinase Inhibitor; Suicide Attempts Related to Antidepressant Medications
- Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Drug safety evaluation of exemestane
- Drug Discovery Today: Therapeutic Strategies - 2006 Editorial
- Qualitative study for finasteride detection in the prostate delivered by reversible inhibition of sperm under guidance – Prostate hair (RISUG-PH<sup>™</sup>) vas injectable implant
- Integrated edge information and pathway topology for drug-disease associations
- First drug for severe alopecia recommended by NICE could benefit 14,000 patients
- A Novel Effect of Acyclovir on Hair Growth in BALB/c Mice: A Promising Future for Finding a New Topical Drug for the Treatment of Hirsutism
- Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using in silico techniques
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- Formulation and evaluation of self-nanoemulsifying drug delivery system for improved oral delivery of exemestane hydrochloride
- The Dutasteride: Miraculous Drug in Alopecia Treatment A Review
- Gallic Acid Nanocrystal Hydrogel: A Novel Strategy for Promoting Wound Healing and Inhibiting Scar Formation
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development